With such striking effects, many scientists see modulating the microbiomes as a promising avenue for improving human health and wellbeing. In recent years, researchers have shown that tweaking the ...

In the second new research review on this subject, Assistant Prof. Ibrahim Bitar, Department of Microbiology, Faculty of Medicine and University Hospital in Plzen, Charles University in Prague, Plzen, ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

CRISPR systems are powerful tools for genetic engineering, but they have their limitations. Now, scientists have discovered almost 200 new CRISPR systems in their native habitat of bacteria, and found ...

The growing threat of antimicrobial-resistant bacteria is calling upon researchers to find alternative ways to treat these infections. Cue CRISPR-Cas technology. Antimicrobial resistance (AMR) is ...

When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they'd stumbled upon a revolutionary tool researchers could ...

The global rise in antibiotic resistance is making bacterial infections harder to treat and increasing the risk of disease spread, severe illness, and death. Once considered miracle drugs, antibiotics ...

Around 10 million. That’s the number of lives forecasters believe we will lose each year by 2050 as bacteria develop defenses against the drugs we use to fight infections. Tackling antibiotic ...

CRISPR Therapeutics recently obtained approval for its gene therapy Casgevy. The therapy could generate close to $4 billion in annual revenue at its peak. A product approval and strong balance sheet ...

Nils Birkholz does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...